Skip to main content

REGULATED INFORMATION IN FRANCE

Regulated information at a glance

Annual financial reports

Half-year financial reports

Quaterly financial information

Report of the Chairman of the Board on corporate governance and internal contro

Fees received by statutory auditors

Total number of voting rights and shares

Share repurchase programs

General meeting preparatory documents

Information published pursuant to article 223-21 of the AMF general regulation

Inside information

Press releases

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

You are about to leave sanofi.com

If you wish to continue to this external website, click Proceed.

It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.

PROCEED